| Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ... Cancer discovery 9 (5), 646-661, 2019 | 631 | 2019 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 378 | 2020 |
| CRISPR gene therapy: applications, limitations, and implications for the future F Uddin, CM Rudin, T Sen Frontiers in oncology 10, 1387, 2020 | 377 | 2020 |
| Lineage plasticity in cancer: a shared pathway of therapeutic resistance JM Quintanal-Villalonga, Álvaro, Chan, HA Yu, D Pe'er, CL Sawyers, ... Nature Reviews Clinical Oncology 17 ((6)), 360-371, 2020 | 313 | 2020 |
| SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization MK Baine, MS Hsieh, WV Lai, JV Egger, AA Jungbluth, Y Daneshbod, ... Journal of Thoracic Oncology 15 (12), 1823-1835, 2020 | 262 | 2020 |
| Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer JM Chan, A Quintanal-Villalonga, VR Gao, Y Xie, V Allaj, O Chaudhary, ... Cancer cell 39 (11), 1479-1496. e18, 2021 | 183 | 2021 |
| Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer CA Stewart, P Tong, RJ Cardnell, T Sen, L Li, CM Gay, F Masrorpour, ... Oncotarget 8 (17), 28575, 2017 | 179 | 2017 |
| CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib T Sen, P Tong, CA Stewart, S Cristea, A Valliani, DS Shames, ... Cancer research 77 (14), 3870-3884, 2017 | 170 | 2017 |
| Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer CA Wohlhieter, AL Richards, F Uddin, CH Hulton, À Quintanal-Villalonga, ... Cell reports 33 (9), 2020 | 137 | 2020 |
| Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7 T Sen, S Moulik, A Dutta, PR Choudhury, A Banerji, S Das, M Roy, ... Life sciences 84 (7-8), 194-204, 2009 | 124 | 2009 |
| Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFκB and AP-1 in the human breast cancer cell line MDA-MB-231 T Sen, A Dutta, A Chatterjee Anti-cancer drugs 21 (6), 632-644, 2010 | 116 | 2010 |
| Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity A Chow, S Schad, MD Green, MD Hellmann, V Allaj, N Ceglia, G Zago, ... Cancer Cell 39 (7), 973-988. e9, 2021 | 110 | 2021 |
| Targeting DNA damage repair in small cell lung cancer and the biomarker landscape T Sen, CM Gay, LA Byers Translational lung cancer research 7 (1), 50, 2018 | 109 | 2018 |
| Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer T Sen, P Tong, L Diao, L Li, Y Fan, J Hoff, JV Heymach, J Wang, LA Byers Clinical Cancer Research 23 (20), 6239-6253, 2017 | 109 | 2017 |
| STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype D Corte CM, S T, G CM, R K, D L, C RJ, R BL, S CA, P VA, G L, F JJ, W Q, ... Journal of Thoracic Oncology 15 (5), 777–791, 2020 | 108 | 2020 |
| Genome wide expression profiling during spinal cord regeneration identifies comprehensive cellular responses in zebrafish SP Hui, D Sengupta, SGP Lee, T Sen, S Kundu, S Mathavan, S Ghosh PloS one 9 (1), e84212, 2014 | 97 | 2014 |
| Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune … T Sen, CM Della Corte, Milutinovic, Snezana, RJ Cardnell, L Diao, ... Journal of Thoracic Oncology 14 (12), 2152-2163, 2019 | 95 | 2019 |
| Targeted Therapies and Biomarkers in Small Cell Lung Cancer H Taniguchi, T Sen, CM Rudin Frontiers Oncology 20 (10), 741, 2020 | 87 | 2020 |
| Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and … RJ Cardnell, L Li, T Sen, R Bara, P Tong, J Fujimoto, AS Ireland, ... Oncotarget 8 (43), 73419, 2017 | 82 | 2017 |
| Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation A Quintanal-Villalonga, H Taniguchi, YA Zhan, MM Hasan, SS Chavan, ... Cancer discovery 11 (12), 3028-3047, 2021 | 77 | 2021 |
